Kilder: 👉
https://www.radio24syv.dk/programmer/24syv-nyheder/19638569/nyheder-0700-19-10-2017
http://www.dr.dk/nyheder/penge/eksperter-giver-novo-nordisk-diabeteshaab-groent-lys-i-usa
http://www.euroinvestor.dk/nyheder/2017/09/29/novo-sydbank-rigtig-positive-nyheder-noget-af-det-var-ventet-ny/13681528
http://www.verdensalt.dk/2016/11/feel-bern-sanders-gar-i-flsket-pa-novo.html
http://www.euroinvestor.dk/nyheder/2017/11/17/novo-analytikere-konkurrents-godkendelse-oeger-konkurrencen/13712793
http://www.euroinvestor.dk/nyheder/2017/11/01/novo-ceo-semaglutid-er-en-noeglemulighed-for-os/13700803
http://www.euroinvestor.dk/nyheder/2017/09/29/novo-fiasp-godkendt-i-usa/13681488
http://borsen.dk/nyheder/virksomheder/artikel/1/346112/novo_nordisk_faar_godkendt_nyt_haemofilimiddel_i_usa.html
https://www.washingtonpost.com/news/wonk/wp/2017/11/24/the-trump-administration-is-taking-on-drug-prices-but-not-drug-companies/?utm_term=.18605b9dc1da
Har masser af artikler om ""nagalase"" - søg og du skal finde:
http://www.verdensalt.dk/search?q=nagalase
********************************************************************************
United States Department of Justice | Tuesday, September 5, 2017 | FOR IMMEDIATE RELEASE | Novo Nordisk Agrees to Pay $58 Million for Failure to Comply with FDA-Mandated Risk Program | Blogger: Holding Big Pharma accountable!!. That's a joke, right!! 💨 Sometimes pharma companies bend the rules. And increasingly, they're getting caught. How do they solve it? By settlement with the U.S. Attorney's office. A slap on the wrist💥Novo Nordisk increased reported operating profit by 8% in the first six months of 2017💥Sales increased by 4% in Danish kroner and by 3% in local currencies to DKK 57.1 billion. Sales of Tresiba® increased by 155% to DKK 3.7 billion (149% in local currencies) Sales of Victoza® increased by 21% to DKK 11.5 billion (18% in local currencies) Sales of Saxenda® increased by 98% to DKK 1.2 billion (90% in local currencies) Sales in North America Operations increased by 5% (2% in local currencies) Sales in International Operations increased by 4% (5% in local currencies).. In short, Novo Nordisk U.S. Holdings Inc., which is a subsidiary of Novo Nordisk A/S of Denmark, the world's largest producer of insulin, trying to sell Victoza in America, ignoring high risk factors and symptoms, linked to dangerous side effects, including pancreatitis and thyroid cancer 💣 BLACK BOX WARNINGS: Risk of thyroid C-cell tumors 💣In detail, the injectable Type 2 diabetes drug Victoza works by stimulating insulin production. It belongs to a class of drugs called GLP-1 mimetics. Studies link Victoza to pancreatitis, thyroid cancer and pancreatic cancer... |
::::WARNING::::
Victoza
The injectable Type 2 diabetes drug Victoza works by stimulating insulin production. It belongs to a class of drugs called GLP-1 mimetics.
Studies link Victoza to pancreatitis, thyroid cancer and pancreatic cancer.
*Please seek the advice of a medical professional before discontinuing the use of this drug.
READ MORE: https://www.justice.gov/opa/pr/novo-nordisk-agrees-pay-58-million-failure-comply-fda-mandated-risk-program
http://www.business.dk/medico/novo-nordisk-indgaar-forlig-paa-366-millioner-kroner
https://www.novonordisk.com/bin/getPDF.2126247.pdf
Overview
VIEW LAWSUIT INFORMATION--> HTTPS://WWW.DRUGWATCH.COM/VICTOZA/